Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erica Landgraf

Nurse Practitioner, Family Greenfield, WI Nurse Practitioner

NPI 1265093348 CMS profile 10547915

8585 W Forest Home Ave, Ste 200, Greenfield, WI 53228

Open in the dashboard

General payments

$14,840

475 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erica Landgraf of Greenfield, WI is reported in the CMS Open Payments database as having received $14,840 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,338 135
2024 General $4,536 111
2023 General $2,804 79
2022 General $2,012 80
2021 General $1,150 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erica Landgraf
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erica Landgraf were reported at $4,338. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erica Landgraf Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,150 $124 $35–$379 $132
2022 $2,012 $141 $44–$430 $149
2023 $2,804 $154 $49–$476 $160
2024 $4,536 $165 $51–$504 $164
2025 $4,338 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $4,246 73 payments
  2. GlaxoSmithKline, LLC. $2,036 86 payments
  3. Genzyme Corporation $1,740 69 payments
  4. Genentech USA, Inc. $1,212 6 payments
  5. Amgen Inc. $687 40 payments
  6. OptiNose US, Inc. $637 42 payments
  7. Teva Pharmaceuticals USA, Inc. $579 26 payments
  8. Regeneron Healthcare Solutions, Inc. $547 15 payments
  9. Novartis Pharmaceuticals Corporation $531 11 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $431 19 payments
  11. Other $2,195 88 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,838 463 payments
  2. Travel and Lodging $1,554 4 payments
  3. Consulting Fee $875 1 payment
  4. Education $574 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $2,464 104 payments
  2. NUCALA $1,529 65 payments
  3. Xolair $1,222 6 payments
  4. FASENRA $915 28 payments
  5. Xhance $637 42 payments
  6. TEZSPIRE Inflammation $632 38 payments
  7. TEZSPIRE Respiratory $591 10 payments
  8. AIRSUPRA $535 12 payments
  9. BREZTRI $468 9 payments
  10. ALVESCO $389 18 payments
  11. Other $5,181 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

285

Median for Nurse Practitioner: 389

Drug cost

$72,763

Median for Nurse Practitioner: $21,885

Branded share of claims

63.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 29 $23,544
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $14,201
Advair Hfa Fluticasone Propion/Salmeterol Brand 22 $9,432
Breo Ellipta Fluticasone/Vilanterol Brand 13 $6,157
Arnuity Ellipta Fluticasone Furoate Brand 23 $6,052
Symbicort Budesonide/Formoterol Fumarate Brand 21 $6,008
Qvar Redihaler Beclomethasone Dipropionate Brand 12 $4,650
Albuterol Sulfate Hfa Albuterol Sulfate Brand 44 $985
Fluticasone Propionate Generic 40 $752
Omeprazole Generic 15 $323

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $400
  • Regeneron Healthcare Solutions, Inc. $171
  • SANOFI-AVENTIS U.S. LLC $99
$670 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $295
$295 — —
NUCALA
  • GlaxoSmithKline, LLC. $283
$283 — —
TEZSPIRE
  • Amgen Inc. $142
  • AstraZeneca Pharmaceuticals LP $133
$275 — —
Xhance
  • OptiNose US, Inc. $188
$188 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record